Just as PYC are accelerating towards the clinic with their mRNA drug candidates in blinding eye diseases, gene therapy appears to be in reverse. The article Roche walks away from 4DMT's eye gene therapy before early-stage trial finishes by Kyle LaHucik, published 24 June 2021, suggests that recent events have put a damper on gene therapy development in eye disease.
The article Roche severs ties with 4D Molecular Therapeutics over blindness gene therapy, marking another setback for the field by Max Gelman, published 24 June 2021, refers to the spate of setbacks.
The setbacks go to both safety and efficacy. The issues with safety go to both immune response to delivery vectors as well as eye inflammation and other adverse events including blindness in the case of separate news from another gene therapy trial. The pendulum is swinging back towards RNA therapeutics.
PYC Price at posting:
15.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)